SCHEMBL1380958

SCHEMBL1380958

CCN(Cc1nc(-c2cccc(C(F)(F)F)c2)oc1C)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 11/20 1.00
NR1H3 Q13133 11/20 1.00
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
DHFR P00374 6/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386135 0.91 NR1H2 (1.00) NR1H2NR1H3ALDH1A1MAPTLMNA
SCHEMBL1381813 0.90 NR1H2 (1.00) NR1H2NR1H3MAPTLMNAHTT
SCHEMBL1380216 0.88 NR1H3 (1.00) NR1H2NR1H3ALDH1A1MAPTLMNA
SCHEMBL1382860 0.87 NR1H2 (0.77) NR1H2NR1H3ALDH1A1LMNADHFR
SCHEMBL1382717 0.86 NR1H2 (0.76) NR1H2NR1H3ALDH1A1LMNADHFR
SCHEMBL1386493 0.86 NR1H2 (0.75) NR1H2NR1H3ALDH1A1LMNADHFR
SCHEMBL2080791 0.85 NR1H2 (0.73) NR1H2NR1H3ALDH1A1LMNAHTT
SCHEMBL1379725 0.85 NR1H2 (0.73) NR1H2NR1H3ALDH1A1MAPTLMNA
SCHEMBL1386176 0.83 NR1H2 (0.71) NR1H2NR1H3ALDH1A1LMNA
SCHEMBL1383376 0.81 NR1H2 (1.00) NR1H2NR1H3MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4809338-B2 2011-11-09 JP claimed
US-7259178-B2 Containing an oxazole ring, e.g., 1,1,1,3,3,3-Hexafluoro-2-{4-[[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-propan-2-ol; the compounds bind to and selectively activate LXR alpha and LXR beta; used to treat diseases such as atherosclerosis and diabetes HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US claimed
CN-1972897-A Novel hexafluoroisopropanol derivative HOFFMANN LA ROCHE (CH) 2007-05-30 CN claimed
EP-1763502-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-21 EP claimed
US-20060004068-A1 Novel hexafluoroisopropanol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-01-05 US claimed
WO-2006000323-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO claimed
US-7897815-B2 Hexafluoroisopropanol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-20100004297-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES DEHMLOW HENRIETTA 2010-01-07 US disclosed
US-7608721-B2 Hexafluoroisopropanol derivatives HOFFMANN-LA ROCHE INC. (US) 2009-10-27 US disclosed
US-20080096937-A1 Novel hexafluoroisopropanol derivatives DEHMLOW HENRIETTA 2008-04-24 US disclosed
US-20070213377-A1 Novel hexafluoroisopropanol derivatives DEHMLOW HENRIETTA 2007-09-13 US disclosed
US-7259178-B2 Containing an oxazole ring, e.g., 1,1,1,3,3,3-Hexafluoro-2-{4-[[5-methyl-2-(3-trifluoromethyl-phenyl)-oxazol-4-ylmethyl]-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-propan-2-ol; the compounds bind to and selectively activate LXR alpha and LXR beta; used to treat diseases such as atherosclerosis and diabetes HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
CN-1972897-A Novel hexafluoroisopropanol derivative HOFFMANN LA ROCHE (CH) 2007-05-30 CN disclosed
EP-1763502-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-03-21 EP disclosed
US-20060004068-A1 Novel hexafluoroisopropanol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-01-05 US disclosed
WO-2006000323-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213377-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885ALDH1A1 2475/4885
US-20100004297-A1 NOVEL HEXAFLUOROISOPROPANOL DERIVATIVES NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885ALDH1A1 2475/4885
US-20080096937-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885ALDH1A1 2475/4885
US-20060004068-A1 Novel hexafluoroisopropanol derivatives NR1H3, NR1H2, NR1I2 NR1H2 2/4885NR1H3 1/4885ALDH1A1 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.